

Reference:	FOI.13417.23
Subject:	Treatment of dermatological conditions
Date of Request:	14 December 2023

Requested:

1. How many patients were treated in the last 4 months (August to November 2023) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib

2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- Age 6-11
- Age 12-17
- Age 18 and above

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated by the Dermatology Department, with the listed medications, during the period 1 August 2023 to 30 November 2023.

Medication	Number
Abrocitinib	0
Acitretin	59
Alitretinoin	9
Azathioprine	12
Baricitinib	*
Ciclosporin	10
Dupilumab	60
Methotrexate	68
Mycophenolate mofetil	*
Pimecrolimus	*
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0

Tacrolimus ointment	6
Tralokinumab	*
Upadacitinib	*

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. Of the patients identified in question 1, the UHB provides, within the table overleaf, the number of patients that received any of the listed medications, by the age groups requested, during the period 1 August 2023 to 30 November 2023.

Age group	Number
Aged 6 -11	9
Aged 12-17	10
Aged 18 and above	209